Esketamine for treatment-resistant depression: Comparing two maintenance schedules in an observational real-world study
Research Square July 9, 2026 Samuel Westenhöfer, Yamina Ehrt, Barbora Provaznikova et al.
Abstract Background : Treatment-resistant depression (TRD) is associated with substantial clinical and socioeconomic burden. Intranasal esketamine has shown efficacy for TRD in clinical trials and real-world studies. However, evidence on optimal maintenance scheduling is limited. We therefore investigated whether two maintenance schedules differing in their inter-dose intervals were associated...